PUBLISHER: DelveInsight | PRODUCT CODE: 1048445
PUBLISHER: DelveInsight | PRODUCT CODE: 1048445
DelveInsight's, "PRMT5 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in PRMT5 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
PRMT5 protein inhibitors Understanding
PRMT5 protein inhibitors: Overview
Protein arginine methyltransferase 5 (PRMT5) is a critical regulatory protein linked to genome organization, cell cycle regulation, and stem cell differentiation1. It forms an active complex with MEP50 and transfers methyl groups from S-adenosylmethoinine (SAM) to histone proteins, transcription factors, and other regulatory proteins. These methylations form mono and symmetrically di-methylated arginine residues. Dysregulation of PRMT5 activity is associated with many cancers including lymphomas, lung cancer, and breast cancer. Additionally, PRMT5 is linked to kidney disease, heart disease, and neurological disorders including Huntington's and Alzheimer's. Recent scientific breakthroughs have caused PRMT5 to emerge as a promising new drug target. New findings in both the specific inhibition of PRMT5 and in metabolic pathways linked to its activity have brought new attention to this important protein.
PRMT5 protein inhibitors Emerging Drugs Chapters
This segment of the PRMT5 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PRMT5 protein inhibitors Emerging Drugs
PRT811, Prelude's second clinical product candidate, is an oral PRMT5 inhibitor under development for patients with PRMT5-dependent cancers, including central nervous system (CNS) tumors such as glioblastoma multiforme (GBM) and primary CNS lymphoma. PRT811 is designed to have high potency and selectivity and optimized brain exposure. PRT811 is being studied in a Phase 1 clinical trial in solid tumors, including GBM and primary central nervous system lymphomas (PCNSL).
Pemrametostat (formerly GSK 3326595) is an oral inhibitor of protein arginine methyltransferase 5 (PRMT 5), being developed by GlaxoSmithKline. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin's lymphoma and solid tumors.
Further product details are provided in the report……..
PRMT5 protein inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PRMT5 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 9+ key companies which are developing the PRMT5 protein inhibitors. The companies which have their PRMT5 protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.
DelveInsight's report covers around 10+ products under different phases of clinical development like
PRMT5 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
PRMT5 protein inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PRMT5 protein inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PRMT5 protein inhibitors drugs.
Key Questions
Current Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
PRMT5 protein inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
PRMT5 protein inhibitors - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Pemrametostat: GlaxoSmithKline
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PRT811: Prelude Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
AMG 193: Amgen
Drug profiles in the detailed report…..
Inactive Products
PRMT5 protein inhibitors Key Companies
PRMT5 protein inhibitors Key Products
PRMT5 protein inhibitors- Unmet Needs
PRMT5 protein inhibitors- Market Drivers and Barriers
PRMT5 protein inhibitors- Future Perspectives and Conclusion
PRMT5 protein inhibitors Analyst Views
PRMT5 protein inhibitors Key Companies
Appendix